S3: Single-cell data from treated cells from ALL patients UPN1-31 with drugs (1) Dasatinib (Bcr-abl inhibitor), (2) Tofacitinib (JAK/STAT inhibitor) and (3) BEZ-235 (PI3k/mTOR inhibitor) derived from using 3 different gating strategies: (1) “All cells,” denoting the entire sample including live and death cells, (2) “Live Only,” denoting the manually gated live cells and (3) “Malignant-cells” denoting cells enriched for malignant white blood cells (blasts), devoid for normal cells, such as T and myeloid cells.

S4: Single-cell data from treated HeLa cells with small molecules (1)TRAIL; (2) Mek inhibitor (GSK); (3) pP38MAPK inhibitor (SB); and (4) PI3K inhibitor (GDC).

S5: Single-cell data from treated cells from ALL patient UPN1 with drugs (1) Dasatinib (Bcr-abl inhibitor), (2) Tofacitinib (JAK/STAT inhibitor) and (3) BEZ-235 (PI3k/mTOR inhibitor).

S6: Single-cell data from treated cells from ALL patient UPN7 with drugs (1) Dasatinib (Bcr-abl inhibitor), (2) Tofacitinib (JAK/STAT inhibitor) and (3) BEZ-235 (PI3k/mTOR inhibitor).

S7: Single-cell data from treated cells from NALM6  cell ine with drugs (1) Dasatinib (Bcr-abl inhibitor), (2) Tofacitinib (JAK/STAT inhibitor) and (3) BEZ-235 (PI3k/mTOR inhibitor).

S8: Single-cell data from treated non-malignant cells from ALL patient UPN1 with drugs (1) Dasatinib (Bcr-abl inhibitor), (2) Tofacitinib (JAK/STAT inhibitor) and (3) BEZ-235 (PI3k/mTOR inhibitor).

S9: Single-cell data from treated non-malignant cells from ALL patient UPN7 with drugs (1) Dasatinib (Bcr-abl inhibitor), (2) Tofacitinib (JAK/STAT inhibitor) and (3) BEZ-235 (PI3k/mTOR inhibitor).